Home » Stocks » BDX

Becton, Dickinson and Company (BDX)

Stock Price: $232.30 USD 3.34 (1.46%)
Updated November 30, 12:32 PM EST - Market open

Stock Price Chart

Key Info

Market Cap 67.37B
Revenue (ttm) 17.12B
Net Income (ttm) 767.00M
Shares Out 290.03M
EPS (ttm) 2.71
PE Ratio 85.72
Forward PE 18.02
Dividend $3.32
Dividend Yield 1.43%

Stock Quote

Trading Day November 30
Last Price $232.30
Previous Close $228.96
Change ($) 3.34
Change (%) 1.46%
Day's Open 230.08
Day's Range 229.97 - 234.04
Day's Volume 1,114,435
52-Week Range 199.25 - 283.16

More Stats

Market Cap 67.37B
Enterprise Value 82.37B
Earnings Date (est) n/a
Ex-Dividend Date Sep 8, 2020
Shares Outstanding 290.03M
Float n/a
EPS (basic) 2.75
EPS (diluted) 2.71
FCF / Share 9.42
Dividend $3.32
Dividend Yield 1.43%
Earnings Yield 1.17%
FCF Yield 4.05%
Payout Ratio 114.90%
Shares Short 2.00M
Short Ratio 1.56
Short % of Float n/a
Beta 0.85
PE Ratio 85.72
Forward PE 18.02
P/FCF Ratio 24.69
PS Ratio 3.94
PB Ratio 2.77
Revenue 17.12B
Operating Income 1.48B
Net Income 767.00M
Free Cash Flow 2.73B
Net Cash -14.99B
Net Cash / Share -51.70
Gross Margin 46.26%
Operating Margin 8.67%
Profit Margin 4.50%
FCF Margin 15.94%
ROA 2.98%
ROE 3.90%
ROIC 5.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (16)

Buy 8
Overweight 2
Hold 6
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(17.92% upside)
Current: $232.30
Target: 273.93
*Average 12-month price target from 14 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-1%8.18%32.17%-3.12%21.41%21.74%4.87%4.49%1.64%-
Gross Profit7,5778,2887,2695,9655,9914,6954,3014,1713,9533,959
Operating Income1,4841,7601,5091,5221,4301,0741,6061,2551,5581,665
Net Income8741,2343111,1009766951,1851,2931,1701,271
Shares Outstanding290270268228213210192194200217
Earnings Per Share2.713.940.604.604.493.355.996.495.595.62
EPS Growth-31.22%556.67%-86.96%2.45%34.03%-44.07%-7.7%16.1%-0.53%-
Dividend Per Share3.
Dividend Growth2.6%2.67%2.74%10.61%10%10.09%10.1%10%9.76%-
Operating Cash Flow3,5393,3302,8652,5502,5591,7301,7461,7171,7601,716
Capital Expenditures-810-957-895-727-693-596-653-588-553-599
Free Cash Flow2,7292,3731,9701,8231,8661,1341,0931,1291,2071,117
Cash & Equivalents2,9376201,25314,2001,9071,5192,7502,6082,1811,563
Total Debt17,93119,39021,49518,87011,55112,8223,9713,9704,1662,720
Net Cash / Debt-14,994-18,770-20,242-4,670-9,644-11,303-1,221-1,362-1,985-1,156
Book Value23,76521,08120,99412,9487,6337,1645,0535,0434,1364,828
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Becton, Dickinson and Company
Country United States
Employees 72,000
CEO Thomas E. Polen

Stock Information

Ticker Symbol BDX
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Medical Instruments & Supplies
Unique Identifier NYSE: BDX
IPO Date April 23, 1962


Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.